Development
Bristol-Myers Squibb Company
BMY
$48.44
$0.631.32%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 45.01B | 44.94B | 45.19B | 45.85B | 46.16B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.01B | 44.94B | 45.19B | 45.85B | 46.16B |
| Cost of Revenue | 10.52B | 10.33B | 10.11B | 9.87B | 9.78B |
| Gross Profit | 34.49B | 34.60B | 35.08B | 35.97B | 36.38B |
| SG&A Expenses | 7.68B | 7.87B | 7.78B | 7.64B | 7.71B |
| Depreciation & Amortization | 9.05B | 9.11B | 9.27B | 9.43B | 9.60B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.45B | 36.56B | 36.49B | 36.32B | 36.29B |
| Operating Income | 8.56B | 8.38B | 8.70B | 9.53B | 9.87B |
| Income Before Tax | 8.44B | 8.63B | 8.70B | 8.80B | 7.71B |
| Income Tax Expenses | 400.00M | 322.00M | 720.00M | 1.47B | 1.37B |
| Earnings from Continuing Operations | 8.04K | 8.30K | 7.98K | 7.33K | 6.35K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.00M | -18.00M | -14.00M | -18.00M | -18.00M |
| Net Income | 8.03B | 8.29B | 7.96B | 7.31B | 6.33B |
| EBIT | 8.56B | 8.38B | 8.70B | 9.53B | 9.87B |
| EBITDA | 18.33B | 18.17B | 18.69B | 19.61B | 20.15B |
| EPS Basic | 3.87 | 3.96 | 3.78 | 3.46 | 2.97 |
| Normalized Basic EPS | 3.02 | 2.90 | 2.94 | 3.11 | 3.12 |
| EPS Diluted | 3.86 | 3.94 | 3.76 | 3.43 | 2.95 |
| Normalized Diluted EPS | 3.01 | 2.88 | 2.92 | 3.09 | 3.09 |
| Average Basic Shares Outstanding | 8.28B | 8.36B | 8.43B | 8.47B | 8.52B |
| Average Diluted Shares Outstanding | 8.31B | 8.40B | 8.49B | 8.53B | 8.59B |
| Dividend Per Share | 2.31 | 2.28 | 2.25 | 2.22 | 2.19 |
| Payout Ratio | 59.12% | 57.08% | 58.92% | 63.53% | 73.24% |